Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

Ananth has more than 20 years’ experience in pharmaceutical consulting across a variety of disciplines, including quantitative systems pharmacology modeling, health economic modeling, systemic literature reviews, indirect treatment comparisons, and complex statistical analyses of clinical and real-world databases required to support regulatory, payer and HTA submissions worldwide.

Matt 通过基于模型的荟萃分析（MBMA），推动已发表的临床结果数据融入开发决策及商业与监管策略。Matt 与临床开发团队密切合作，确保在做出最关键决策的时候，能利用 MBMA 发挥最佳影响力。

Douglas W. Chung is a highly experienced scientist and consultant specializing in mechanistic modeling to support drug discovery and development. His background is in biomedical engineering and his focus is in quantitative systems pharmacology with over 12 years of experience consulting in biotech and pharmaceuticals. His passion is to grow the field of quantitative pharmacology by expanding diversity in people, fields of expertise, and clinical trial populations.

作为一名应用卫生经济学家和市场准入战略专家，Roman 亲自领导了数百项与产品价值展示相关的全球市场准入、HEOR 和真实世界证据方面的工作，并在与支付方和 HTA 机构的正式和非正式交流中积累了丰富的经验。